PD-1 inhibitor + nedaplatin + paclitaxel

This drug combination consists of a PD-1 inhibitor, nedaplatin, and paclitaxel. - **PD-1 inhibitor** is an immune checkpoint blockade agent that targets the programmed death 1 (PD-1) receptor on T cells. By blocking PD-1 interaction with its ligand PD-L1, it prevents tumor cells from evading immune detection and destruction, thereby enhancing antitumor immunity. This class of drugs has shown durable responses in various cancers but may have limited efficacy as monotherapy in some patients[1][2][3][4][5]. - **Nedaplatin** is a platinum-based chemotherapy agent similar to cisplatin but with potentially different toxicity profiles; it forms DNA crosslinks that inhibit DNA replication and transcription leading to cancer cell death. - **Paclitaxel** is a taxane chemotherapy drug that stabilizes microtubules and prevents their disassembly during mitosis, causing mitotic arrest and apoptosis of cancer cells. It is used widely for ovarian, breast, lung cancers among others[6][8][10]. The combination leverages immunotherapy (PD-1 inhibition) alongside cytotoxic chemotherapy (nedaplatin + paclitaxel) to enhance antitumor effects by both direct tumor cell killing and activation of the immune system.